Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cytokine-induced killer cells
- Development stage
- Unknown
- Lead developer
- Stanford University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Cytokine-induced killer (CIK) cells are an ex vivo-expanded cellular immunotherapy developed by Robert Negrin and colleagues at Stanford University for the treatment of hematologic malignancies, including multiple myeloma. These cells are a unique population of T cells that express both T-cell (CD3) and natural killer (NK) cell (CD56) markers, typically generated by culturing peripheral blood lymphocytes with a sequence of interferon-gamma (IFN-γ), anti-CD3 monoclonal antibody (OKT3), and interleukin-2 (IL-2). CIK cells exert potent, non-MHC-restricted cytotoxic activity against tumor cells primarily through the NKG2D receptor pathway. A significant clinical advantage of this therapy is its ability to provide a graft-versus-leukemia effect with a markedly attenuated capacity for inducing graft-versus-host disease (GVHD) compared to conventional donor lymphocyte infusions, making it a viable post-transplant immunotherapy option.
- Other names
- CD3+CD56+ cellsNegrin CIK cellsCytokine-induced killer cells (Robert Negrin)
Beyond the preview
Go deeper on Cytokine-induced killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytokine-induced killer cells.